An Interview with Boris Bastian
Appointed Chair of the Department of Pathology at Memorial Sloan-Kettering in April 2010, Dr. Bastian leads pathologists and clinicians in finding new ways to integrate genetic information with traditional clinical observations to diagnose cancer and guide treatment.
Saturday, January 1, 2011
Craig Thompson Named President of Memorial Sloan-Kettering
Nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center in August 2010. He also becomes President of Gerstner Sloan-Kettering Graduate School of Biomedical Sciences.
Wednesday, December 15, 2010
Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered
An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.
Wednesday, November 17, 2010
Memorial Sloan-Kettering Enters Agreement to Develop New Cancer Drug
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan-Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
Friday, October 1, 2010
